AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32176061 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with carboplatin-paclitaxel or concurrent chemo-brachytherapy (CCBT)
Number of subjects: 52
Study 32176061 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone or CCBT
Number of subjects: 52
Study 32176061 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with chemotherapy or CCBT
Number of subjects: 52
Study 35501515 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-infusion cooling time (PICT) of 45 min
Number of subjects: 91
Study 35501515 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-infusion cooling time (PICT) of 20 min
Number of subjects: 91
Study 35501515 — intervention group
Group type: COMPARATOR
Intervention: Standard post-infusion cooling time (PICT) of 90 min
Number of subjects: 91
Study 35501515 — intervention group
Group type: EXPERIMENTAL
Intervention: Dean scale assessment
Number of subjects: 91
Study 35501515 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCAE assessment
Number of subjects: 91
Study 34312774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen‐gonadotropin
Number of subjects: 134
Study 34312774 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole‐gonadotropin
Number of subjects: 134
Study 34312774 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin only
Number of subjects: 134
Study 35037319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat-based support (CBS, n=304)
Number of subjects: 679
Study 35037319 — intervention group
Group type: COMPARATOR
Intervention: Text-based support (TBS, n=375)
Number of subjects: 679
Study 35037319 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged participants (both CBS and TBS)
Number of subjects: 679
Study 33919195 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling (DDN)
Number of subjects: 34
Study 33919195 — intervention group
Group type: COMPARATOR
Intervention: Ischemic Compression Technique (ICT)
Number of subjects: 34
Study 36348385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily as maintenance therapy
Number of subjects: 51
Study 36348385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily as treatment
Number of subjects: 51
Study 36348385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (both maintenance and treatment)
Number of subjects: 51
Study 33588088 — intervention group
Group type: EXPERIMENTAL
Intervention: CRRT at 70 ml/kg/h
Number of subjects: 30
Study 33588088 — intervention group
Group type: COMPARATOR
Intervention: CRRT at 35 ml/kg/h
Number of subjects: 30
Study 32134289 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback on writing fluency
Number of subjects: 0
Study 35123660 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg) once daily for up to 14 days plus standard of care
Number of subjects: 101
Study 35123660 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 101
Study 33128066 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (Preexposure prophylaxis) at 70% coverage
Number of subjects: 11245
Study 33128066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PrEP)
Number of subjects: 11245
Study 32552774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluralaner (Bravecto®) administered at a minimum dose of 25 mg/kg body weight, one time on Day 0.
Number of subjects: 20
Study 35731547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aim2Be mHealth app
Number of subjects: 214
Study 33527377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on demonstration of a class IV composite restoration
Number of subjects: 0
Study 33527377 — intervention group
Group type: COMPARATOR
Intervention: Video-supported demonstration of a class IV composite restoration
Number of subjects: 0
Study 35853489 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injection (AM)
Number of subjects: 113
Study 35853489 — intervention group
Group type: COMPARATOR
Intervention: Sham (SM)
Number of subjects: 113
Study 35853489 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection every other month (AEOM)
Number of subjects: 113
Study 34031331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise (PFME) intervention
Number of subjects: 30
Study 32089798 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast
Number of subjects: 60
Study 32089798 — intervention group
Group type: COMPARATOR
Intervention: Written
Number of subjects: 60
Study 36276114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 60
Study 36276114 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 33027403 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text messages
Number of subjects: 156
Study 33027403 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly text messages
Number of subjects: 156
Study 33027403 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 156
Study 33027403 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention (both weekly and biweekly)
Number of subjects: 156
Study 36578007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological intervention
Number of subjects: 120
Study 36578007 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-attentional intervention
Number of subjects: 120
Study 36578007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal intervention
Number of subjects: 120
Study 36578007 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual (baseline)
Number of subjects: 120
Study 36578007 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment (2 months post-intervention)
Number of subjects: 120
Study 32162321 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound protector
Number of subjects: 212
Study 32162321 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical drapes
Number of subjects: 212
Study 32162321 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound protector (subanalysis)
Number of subjects: 212
Study 32162321 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical drapes (subanalysis)
Number of subjects: 212
Study 35643951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (HDP) 60 mg daily (tapered to 0 mg within 12 weeks)
Number of subjects: 395
Study 35643951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (LDP) 10 mg daily (tapered to 0 mg within 12 weeks)
Number of subjects: 395
Study 35643951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 35643951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (HDP)
Number of subjects: 395
Study 35643951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (LDP)
Number of subjects: 395
Study 32522106 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 0
Study 32522106 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5-FU/LV) chemotherapy
Number of subjects: 0
Study 35041742 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 112
Study 35041742 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with dexamethasone
Number of subjects: 112
Study 33296079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein enteral nutrition (63 or 100 g/L protein) for ≤28 days
Number of subjects: 120
Study 33296079 — intervention group
Group type: COMPARATOR
Intervention: Usual practice enteral nutrition (lower protein doses)
Number of subjects: 120
Study 35023050 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy load (HEV)
Number of subjects: 16
Study 35023050 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate load (MOD)
Number of subjects: 16
Study 35023050 — intervention group
Group type: EXPERIMENTAL
Intervention: Light load (LIT)
Number of subjects: 16
Study 32698959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med‐D)
Number of subjects: 29
Study 32698959 — intervention group
Group type: COMPARATOR
Intervention: Western-type diet (Control‐D)
Number of subjects: 29
Study 35274295 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 165
Study 32151511 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Transversus Thoracis Muscle Plane Block (TTP group)
Number of subjects: 100
Study 33051948 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delirium (n = 17)
Number of subjects: 70
Study 33051948 — intervention group
Group type: COMPARATOR
Intervention: Patients without delirium (n = 53)
Number of subjects: 70
Study 33051948 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 70
Study 33075434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 119
Study 33075434 — intervention group
Group type: COMPARATOR
Intervention: Just-play (no regulation)
Number of subjects: 119
Study 33075434 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state HRV
Number of subjects: 119
Study 33075434 — intervention group
Group type: EXPERIMENTAL
Intervention: State HRV
Number of subjects: 119
Study 36205850 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norm message
Number of subjects: 205
Study 36205850 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm message
Number of subjects: 205
Study 36205850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both messages
Number of subjects: 205
Study 36205850 — intervention group
Group type: COMPARATOR
Intervention: Neither message
Number of subjects: 205
Study 32612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive (COC)
Number of subjects: 24
Study 32612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive Vaginal Ring (CVR)
Number of subjects: 24
Study 32612574 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 34797506 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide + ADT
Number of subjects: 455
Study 33043969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesatolimod (1-12 mg)
Number of subjects: 48
Study 33043969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesatolimod (6 mg)
Number of subjects: 48
Study 33043969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 35396289 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based photoplethysmography application assessment
Number of subjects: 236
Study 35396289 — intervention group
Group type: COMPARATOR
Intervention: Modified Allen's test (MAT)
Number of subjects: 236
Study 34216380 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLU-C10D value set generation
Number of subjects: 1010
Study 32721009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen, 1 g, starting at the beginning of surgery and repeated every 6 hours until 48 postoperative hours or hospital discharge
Number of subjects: 570
Study 32721009 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 570
Study 32721009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 570
Study 35873893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C infusion (1.5 g/6 h for 4 days)
Number of subjects: 40
Study 35873893 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mg vitamin C/day for 4 days)
Number of subjects: 40
Study 32370588 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC pathway adherence
Number of subjects: 0
Study 32370588 — intervention group
Group type: COMPARATOR
Intervention: ABC pathway adherence (multimorbidity group)
Number of subjects: 0
Study 32370588 — intervention group
Group type: COMPARATOR
Intervention: ABC pathway adherence (polypharmacy group)
Number of subjects: 0
Study 32370588 — intervention group
Group type: COMPARATOR
Intervention: ABC pathway adherence (hospitalization group)
Number of subjects: 0
Study 33177370 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 60
Study 33177370 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (video on a tablet)
Number of subjects: 60
Study 32079967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten Top Tips (10TT) intervention
Number of subjects: 0
Study 36371162 — intervention group
Group type: EXPERIMENTAL
Intervention: MPVC (MSmonitor-Plus and Video calling Care)
Number of subjects: 208
Study 36371162 — intervention group
Group type: COMPARATOR
Intervention: CAU (Care as Usual)
Number of subjects: 208
Study 34578862 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Kestose supplementation (10 g/day for 12 weeks)
Number of subjects: 0
Study 34578862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34578862 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Kestose supplementation
Number of subjects: 0
Study 34578862 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 32833935 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial, pharmacist-delivered phone-based telehealth intervention
Number of subjects: 281
Study 32833935 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 281
Study 35688801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS)
Number of subjects: 0
Study 35688801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (C-tDCS)
Number of subjects: 0
Study 35688801 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 32761611 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation program (4 weeks)
Number of subjects: 149
Study 32761611 — intervention group
Group type: COMPARATOR
Intervention: Control group managed according to enhanced recovery after surgery principles supplemented by nutritional care
Number of subjects: 149
Study 35357405 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed chart
Number of subjects: 121
Study 35357405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone app
Number of subjects: 121
Study 35357405 — intervention group
Group type: EXPERIMENTAL
Intervention: Website test
Number of subjects: 121
Study 33422499 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade™ (PPB)
Number of subjects: 108
Study 33422499 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 108
Study 35081757 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative messages
Number of subjects: 300
Study 35081757 — intervention group
Group type: COMPARATOR
Intervention: Statistics messages
Number of subjects: 300
Study 33226202 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (120 kVp and standard weight‐adapted CM dose)
Number of subjects: 126
Study 32257154 — intervention group
Group type: EXPERIMENTAL
Intervention: Community activism/mobilisation portion of Indashyikirwa, based on SASA! program model.
Number of subjects: 2800
Study 35172871 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM plus original antihypertensive regimen
Number of subjects: 400
Study 35172871 — intervention group
Group type: COMPARATOR
Intervention: Control (original antihypertensive regimen only)
Number of subjects: 400
Study 616874253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 30
Study 616874253 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study 36098658 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who developed T2D (1,614 individuals)
Number of subjects: 2499
Study 36098658 — intervention group
Group type: COMPARATOR
Intervention: Participants who remained without diabetes (885 individuals)
Number of subjects: 2499
Study 32619274 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc protocol
Number of subjects: 120
Study 32619274 — intervention group
Group type: COMPARATOR
Intervention: Manual protocol
Number of subjects: 120
Study 32619274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-income persons
Number of subjects: 120
Study 32619274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 120
Study 34839470 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nylon dressing
Number of subjects: 649
Study 34839470 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 649
Study 34462279 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg intrauterine system (LNG‐IUS 52 mg)
Number of subjects: 208
Study 34462279 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic niche resection
Number of subjects: 208
Study 32952045 — intervention group
Group type: EXPERIMENTAL
Intervention: Delegation to MFAs with extended qualification (EVA, VERAH, VERAH Plus)
Number of subjects: 2404
Study 32952045 — intervention group
Group type: COMPARATOR
Intervention: Delegation to standard qualified MFAs
Number of subjects: 2404
Study 33678048 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby® (MTB) home visiting program
Number of subjects: 97
Study 32652300 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (40 mg for 14 days) + Metformin (1000 mg daily for 3 months)
Number of subjects: 60
Study 32652300 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (40 mg for 14 days) + Placebo
Number of subjects: 60
Study 32148744 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation with video-game based therapy for 8 weeks, 5 sessions per week
Number of subjects: 50
Study 32148744 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (control group) for 8 weeks, 5 sessions per week
Number of subjects: 50
Study 34757164 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric height-indexed LAVmax
Number of subjects: 986
Study 34757164 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric height-indexed LAVmax
Number of subjects: 986
Study 34757164 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-indexed LAVmin
Number of subjects: 986
Study 34757164 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVmax > 22.1 mL/m1.72
Number of subjects: 986
Study 33245533 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin + mirabegron 50 mg
Number of subjects: 568
Study 33245533 — intervention group
Group type: COMPARATOR
Intervention: tamsulosin + placebo
Number of subjects: 568
Study 32870158 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMAP Mobile (WMM) intervention
Number of subjects: 143
Study 35820740 — intervention group
Group type: EXPERIMENTAL
Intervention: Manometry-guided therapeutic thoracentesis
Number of subjects: 61
Study 34024687 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn injury
Number of subjects: 9099
Study 34024687 — intervention group
Group type: COMPARATOR
Intervention: No burn injury (Control)
Number of subjects: 9099
Study 32008782 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR1.2 (cluster remover take‐off milk flow threshold of 1.2 kg/min)
Number of subjects: 689
Study 32008782 — intervention group
Group type: COMPARATOR
Intervention: ACR0.8 (cluster remover take‐off milk flow threshold of 0.8 kg/min)
Number of subjects: 689
Study 32008782 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR1.2
Number of subjects: 689
Study 32008782 — intervention group
Group type: COMPARATOR
Intervention: ACR0.8
Number of subjects: 689
Study 34743348 — intervention group
Group type: EXPERIMENTAL
Intervention: FPC 6.75 mg Fe IV predialyzer
Number of subjects: 27
Study 34743348 — intervention group
Group type: EXPERIMENTAL
Intervention: FPC 6.75 mg Fe IV postdialyzer
Number of subjects: 27
Study 34743348 — intervention group
Group type: COMPARATOR
Intervention: FPC 2 μM (110 μg Fe/L of hemodialysate)
Number of subjects: 27
Study 34743348 — intervention group
Group type: EXPERIMENTAL
Intervention: FPC IV infusion of 6.75 mg iron during 3 hours of HD
Number of subjects: 27
Study 34743348 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bioequivalence assessment
Number of subjects: 27
Study 34743348 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety of IV FPC
Number of subjects: 27
Study 34092587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial treatment (FT)
Number of subjects: 60
Study 34092587 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 60
Study 34092587 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, CG)
Number of subjects: 60
Study 35688442 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX‐011 (400 mg bupivacaine/12 mg meloxicam) with multimodal analgesic regimen (preoperative acetaminophen, celecoxib, pregabalin, and postoperative acetaminophen and celecoxib)
Number of subjects: 51
Study 35688442 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX‐011 with MMA regimen
Number of subjects: 51
Study 33205642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died in hospital due to CDI (group A)
Number of subjects: 180
Study 33205642 — intervention group
Group type: COMPARATOR
Intervention: Patients who survived (group B)
Number of subjects: 180
Study 33205642 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 180
Study 33205642 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 180
Study 33205642 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 180
Study 33205642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower albumin level
Number of subjects: 180
Study 33205642 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 180
Study 33164410 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoji Recipe + Rosuvastatin Calcium 10 mg·d(‐1)
Number of subjects: 125
Study 33164410 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin Calcium 20 mg·d(‐1)
Number of subjects: 125
Study 33164410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Xiaoji and control)
Number of subjects: 125
Study 36031894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention for couples (8-week duration)
Number of subjects: 16
Study 32828663 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality headset
Number of subjects: 30
Study 32828663 — intervention group
Group type: COMPARATOR
Intervention: Laptop screen
Number of subjects: 30
Study 32078394 — intervention group
Group type: EXPERIMENTAL
Intervention: CASH‐AA + MIP
Number of subjects: 145